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Abstract
Background: Three-dimensional conformal radiation therapy (3DCRT)/intensity-modulated radiation therapy (IMRT)
combined with or without transcatheter arterial chemoembolization (TACE) for locally advanced hepatocellular
carcinoma (HCC) has shown favorable outcomes in local control and survival of locally advanced HCC. However,
intra-hepatic spreading and metastasis are still the predominant treatment failure patterns. Sorafenib is a
multikinase inhibitor with effects against tumor proliferation and angiogenesis. Maintenance Sorafenib would
probably prevent or delay the intrahepatic and extrahepatic spread of HCC after radiotherapy, which provides the
rationale for the combination of these treatment modalities.
Methods and design: Patients with solitary lesion (bigger than 5 cm in diameter) histologically or cytologically
confirmed HCC receive TACE (1-3 cycles) plus 3DCRT/IMRT 4-6 weeks later. Maintenance Sorafenib will be
administered only for the patients with non-progression disease 4 to 6 weeks after the completion of radiotherapy.
The dose will be 400 mg, p.o., twice a day. Sorafenib will be continuously given for 12 months unless intolerable
toxicities and/or tumor progression. If no more than 3 patients discontinue Sorafenib treatment who experience
dose-limiting toxicity after necessary dose modification and delay and/or radiation-induced liver disease in the first
15 enrolled patients, the study will recruit second fifteen patients for further evaluating safety and efficacy of
treatment. Hypothesis of the current study is that Sorafenib as a maintenance therapy after combined therapy of
3DCRT/IMRT and TACE is safe and superior to radiotherapy combined with TACE alone in terms of time to
progression (TTP), progression-free survival (PFS) and overall survival (OS) in comparison to historical data.
Discussion: A recent meta-analysis showed TACE in combination with radiotherapy, improved the survival and the
tumor response of patients, and was thus more therapeutically beneficial. In this study, local therapy for HCC is the
combination of TACE and radiotherapy. Radiation exposure as a kind of stress might induce the compensatory
activations of multiple intracellular signaling pathway mediators, such as PI3K, MAPK, JNK and NF-kB. Vascular
endothelial growth factor (VEGF) was identified as one factor that was increased in a time- and dose-dependent
manner after sublethal irradiation of HCC cells in vitro, translating to enhanced intratumor angiogenesis in vivo.
Therefore, Sorafenib-mediated blockade of the Raf/MAPK and VEGFR pathways might enhance the efficacy of
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Background
Hepatocellular carcinoma (HCC) is the 6th most com-
mon cancer and is the third leading cause of cancer-
related death worldwide [1]. In Shanghai, China, HCC
was also one of the most common malignancies with
the incidence of 41.91/100 000 and 16.52/100 000 for
male and female, respectively, which ranked the 4th and
5th according to the epidemiological survey in 2006.
Unfortunately, the overall 5-year survival rate for all
HCC patients has remained no more than 5% [1]. Sur-
gery is considered as the curative option for HCC. How-
ever, when diagnosed, only 20 percent of HCC patients
in Shanghai are surgically operable. Whereas, 80% of
HCC are either technically unresectable due to local
advanced tumor, or medically inoperable due to severe
hepatic cirrhosis [2]. For non-surgical managements
transcatheter arterial chemoembolization (TACE) has
been widely used, and demonstrated its benefit in
improving survival of unresectable HCC, compared to
the supportive care [3-6], although the benefit was
slight.
Three-dimensional conformal radiation therapy
(3DCRT)/intensity-modulated radiation therapy (IMRT)
has made it possible to escalate irradiation dose to focal
HCC without undue dose-limiting toxicity, and has
increasingly been recognized as a potentially curative
option for patients with HCC [7]. Radiotherapy com-
bined with or without TACE for HCC has shown favor-
able outcomes in local control and survival with median
survival time of 10 months to 25 months [7] and 3-year
survival of around 30% [8]. However, intra- and extra-
hepatic spreading is still the predominant failure pattern,
as reported by Cheng JC et al. They found that after
radiotherapy over half of patients failed in intrahepatic
multiple recurrences outside irradiation field and extra-
hepatic metastasis, and only three patients had in-field
progression [9]. Liang SX et al reported local failure of
48% and distant metastasis of 19%, including lungs,
bones and other sites [8]. In a dose escalation clinical
study, which was just completed recently by our insti-
tute, out of 40 patients in this trial, 21 patients devel-
oped intrahepatic out-of-field failures and 5 had distant
metastases (Ren ZG, Zhao JD, Gu K, et al: Three-dimen-
sional conformal radiation therapy and intensity modu-
lated radiation therapy combined with transcatheter
arterial chemoembolization for locally advanced hepato-
cellular carcinoma: an irradiation dose escalation study,
submitted). These findings suggest that local and distant
failures are still the obstacles for further improvement
of outcome in HCC patients after irradiation, and clearly
there is a need for novel and more effective therapeutic
strategies.
Sorafenib is a multikinase inhibitor with effects against
tumor proliferation and angiogenesis. The strong evi-
dence that Sorafenib achieved significantly survival ben-
efit in advanced HCC derived from SHARP trial [10]. In
this multi-center randomized study, compared to the
placebo arm, patients receiving Sorafenib had a longer
median survival (10.7 mo vs 7.9 mo; HR 0.69, P < 0.01)
and time to progression (TTP) (HR 0.58, P < 0.01).
Another phase III clinical trial concluded that Sorafenib
was well tolerated and effective in the treatment of
advanced HCC in Asia-Pacific region [11].
T h el o wt u m o rr e s p o n s er a t e( l e s st h a n5 % )w i t h
monotherapy of Sorafenib in clinical trials mentioned
before indicates that it is unlikely to cure HCC in the
absence of local therapies. When Sorafenib is admini-
strated after radiotherapy, it would probably have the
effects of preventing or delaying the intrahepatic and
extrahepatic spreading of HCC, which provides the
rationale for the combination of these treatment
modalities.
Hypothesis of the current study is that Sorafenib as a
maintenance therapy after combined therapy of 3DCRT/
IMRT and TACE is safe, and the outcome is superior to
radiotherapy plus TACE in terms of TTP, progression-
free survival (PFS) and overall survival (OS) in compari-
son to historical data.
Methods and Design
Study design
The present study is a non-randomized, uncontrolled
single-arm, non-blinded, single-center phase I/II clinical
trial. The treatment schedule is shown in Figure 1.
Dose-limiting toxicity is defined as follows: Safety and
tolerability are evaluated monthly during the period of
maintenance Sorafenib. Dose-limiting toxicity (DLT) is
defined as: (1) grade 3 hand-foot skin reaction (Table 1);
(2) grade 3 and grade 4 non-hematological toxicity,
except for hand-foot skin reaction (Table 2); (3) grade 3
and grade 4 hematological toxicity (Table 3); (4) grade 2
to grade 4 hypertension detailed in Table 4. Onset of
radiation-induced liver disease (RILD) within 4 months
after radiation is an intolerable toxicity, which manifests
as either anicteric elevation of alkaline phosphatase
(AKP) level of at least two fold of upper normal level
(ULN) and nonmalignant ascites (classic RILD) or ele-
vated transaminases of at least five fold of the ULN or
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(nonclassic RILD). However, progression of HCC should
be ruled out for the diagnosis of RILD. Toxicity is
graded according to the National Cancer Institute com-
mon terminology criteria for adverse events (CTCAE)
version 3.0.
If no more than 3 patients discontinue Sorafenib treat-
ment who experience DLT after necessary dose modifi-
cation which follow the predefined dose levels (Table 5)
and delay (Table 2, 3, 4 and 6) and/or RILD in the first
15 enrolled patients, the study will recruit second fifteen
patients for further evaluating safety and efficacy of
treatment.
Study objectives
The study is designed to investigate the safety, tolerabil-
ity and also the efficacy of Sorafenib as maintenance for
non-progression locally advanced HCC patients, who
have received combined therapy of 3DCRT/IMRT and
TACE. The primary outcome measure is the safety and
tolerability of Sorafenib maintenance for a scheduled
period of twelve months. The secondary outcome mea-
sures TTP, PFS and OS.
Trial organization
This trial has been designed by the Department of
Radiation Oncology and Integrative Oncology in coop-
eration with Department of Interventional Radiology.
The trial is an investigator-initiated trial and is sup-
ported partly by Bayer Schering Pharma, China.
Coordination and monitoring
The trial is coordinated by the clinical trial office of
Fudan University Shanghai Cancer Center, Shanghai,
China. During patient recruitment in this center moni-
toring on site is performed according to good clinical
practice (GCP) guidelines. The trial is registered with
the ClinicalTrials.gov (NCT00999843). The data man-
agement will be performed by the clinical trial office of
Fudan University Shanghai Cancer Center, Shanghai,
China.
Ethical approval
The final protocol was approved on February 2, 2009 by
Research Ethics Committee of Fudan University Shang-
hai Cancer Center (Reference number: 090168-9).
Patient selection
All of inclusion criteria should be satisfied:
1. Age of equal or older than 18 years with a life
expectancy of at least 12 weeks;
2. Karnofsky performance status (KPS) of ≥70;
3. Histologically or cytologically confirmed HCC;
4. BCLC stage B, solitary lesion (bigger than 5 cm in
diameter) with tumor burden less than 50% of total liver
volume;
5. Liver function of Child-Pugh A;
6. Technically unresectable, medically inoperable, or
surgery declined by the patient;
7. Adequate renal function (serum creatinine concen-
tration ≤ 1.5 ×ULN), and hepatic function (serum total
bilirubin level ≤ 2 × ULN, serum aspartate and alanine
transaminase levels ≤ 2.5 × ULN); and adequate bone
marrow reservation (absolute neutrophil count ≥ 1500
cells/mm
3,p l a t e l e tc o u n t≥ 60 000 cells/mm
3,a n d
hemoglobin ≥ 8.5 g/dL); and prothrombin time ≤ 1.5 ×
ULN;
8. Signed informed consent must be obtained prior to
any study specific procedure.
The followings are the exclusion criteria:
Table 1 Hand-foot skin reaction grading
Grade
1
Numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort, which does not
disrupt normal activities.
Grade
2
Painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient’s activities.
Grade
3
Moist desquamation, ulceration, blistering or severe pain of the hands and/or feet and/or severe discomfort that causes the patient to be
unable to work or perform activities of daily living.
Table 2 Non-hematologic criteria for dose delay and dose
modification of sorafenib (except for skin toxicity)
#
Grade Dose Delay Dose Modification
Grade 0-2 Treat on time No Change
Grade 3 Delay* until ≤ Grade 2 Decrease one dose level^
Grade 4
#: Also excludes nausea/vomiting that has not been premedicated, and
diarrhea.
*: If no recovery after 30-day delay, treatment will be discontinued.
^: If more than 2 dose reductions are required, treatment will be
discontinued.
Table 3 Hematologic criteria for dose delay and dose
modification of sorafenib
Grade Dose Delay Dose Modification
Grade 0-2 Treat on time No Change
Grade 3 Delay* until ≤ Grade 2 Decrease one dose level^
Grade 4
*: If no recovery after 30-day delay, treatment will be discontinued.
^: If more than 2 dose reductions are required, treatment will be
discontinued.
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metastases
2. Previous received systemic therapy for liver cancer;
3. History of radiotherapy to the liver;
4. Indistinct tumor boundary on CT/MRI images;
5. Previous or concurrent malignancies, with the
exception of adequately treated basal cell carcinoma of
the skin or in situ carcinoma of the cervix or superficial
bladder tumors [Ta,T is and T1];
6. History of cardiac disease: congestive heart failure >
NYHA class 2, active CAD, cardiac arrythmias requiring
anti-arrhythmic therapy or uncontrolled hypertension
within the last 12 months;
7. Concurrent uncontrolled medical conditions and
recent bleeding diathesis;
8. Pregnancy or breast feeding;
9. Investigational drug therapy outside of this trial
during or within 4 weeks of study entry;
10. Psychiatric or medical unstable conditions that
compromise the patient’s ability to give informed
consent.
TACE before radiation therapy
TACE as a standard treatment for this specific patient
population will be implemented before radiotherapy.
The chemotherapeutic agents injected are a combination
of one platinum-containing drug, for instance, cis-plati-
num (DDP), carbon platinum (CBP) or Oxaliplatin (L-
OHP) and one anti-tumor antibiotics drug, for instance,
mitomycin (MMC), adrimycin (ADM) or Epi-ADM.
TACE will be carried out with an interval of 4-6 weeks
between cycles. Total course of TACE will be termi-
nated if more than 75% of tumor volume occupied by
iodine oil in CT scan one month after 1, 2 or 3 cycles
of TACE. From our previous experience, if three cycles
of TACE have not achieved adequate iodine deposition,
the chance of getting more iodine accumulation is quite
low with furthermore TACE. Moreover, excessive TACE
would cause more severe damage to Chinese HCC
patients with hepatic cirrhosis. Therefore, at most 3
cycles of TACE will be carried out before radiation
therapy.
Radiation therapy
Radiotherapy is delivered 4-6 weeks after the last cycle
of TACE. Active breath coordinator (ABC) is applied to
control the liver motion due to respiration [12]. Patients
undergo CT simulation with individualized immobiliza-
tion vacuum lock. Helical CT scan is performed with 5
mm of thickness and a pitch of 1:1. Scan scope is from
3-4 cm above the dome of diaphragm to the level below
right kidney. Gross tumor volume (GTV) in liver is deli-
neated on the axial simulation CT images with the aid
of deposited iodinated-oil, MRI, or contrast enhanced
CT images. Clinical target volume (CTV) is formed by
adding a uniform 5-8 mm around GTV within the liver.
The extra margin needed for internal target volume
(ITV) is individually decided based on the reproducibil-
ity of lesion/liver position when ABC is applied. Plan-
ning target volume (PTV) is formed by adding a margin
of 6 mm around ITV. 3DCRT treatment plan is pre-
ferred, but IMRT would also be considered when dose
constrains of normal organs and tumor could not be
satisfied with 3DCRT. For 3DCRT or IMRT plan, multi-
ple co-planar or non-coplanar portals are designed with
the intention to reduce the dose to normal liver and the
Table 4 Procedure for hypertension emerged by sorafenib treatment
Grade Management/Next Dose
Grade 1 Consider increased BP monitoring
Grade 2 Asymptomatic and diastolic BP < 110
mm Hg
Begin anti-hypertensive therapy and continue the agent
Grade 2 Symptomatic/persistent or diastolic
BP ≥ 110 mmHg or
1. Agent should be held until symptoms resolve and diastolic BP ≤ 100 mmHg; also treat patient
with anti-hypertensives and when agent is restarted, reduce by 1 dose level.*
Grade 3 2. If diastolic BP not controlled (≤ 100) on therapy, reduce another dose level.^
Grade 4 Discontinue protocol therapy
*: May be able to resume full dose later.
^: Patients requiring > 2 dose reductions should go off protocol therapy.
Figure 1 Treatment Schedule.
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IMRT plan, we use a simplified IMRT technique, which
applies: (1). The number of portals is ≤ 5; (2). The num-
ber of beam lit (subfield) is ≤ 5 ;( 3 ) .T h es i z eo ft h e
smallest subfield is ≥ 5 cm × 5 cm. The radiation dose
prescribed to tumor is as high as possible, but the maxi-
mum doses are 62 Gy and 52 Gy for patients with
tumor diameter less than 10 cm and ≥ 10 cm, respec-
tively. The dose is delivered by conventional fractiona-
tion, i.e., 2 Gy/fraction, one fraction per day and 5
fractions per week.
The organs at risk (OAR) contoured include liver,
bilateral kidneys, spinal cord, stomach and duodenum.
Dose constraint to liver is mean dose to normal liver
(MDTNL) (total liver volume minus PTV) of ≤ 23 Gy,
and the dose volume histogram (DVH) is in a tolerable
area based on our previous experience: V5 of <86%, V10
of <68%, V15 of <59%, V20 of <49%, V25 of <35%, V30 of
<28%, V35 of <25%, and V40 of <20% [13]. Should one
kidney receive >20 Gy, >90% of the other kidney should
be excluded from the primary beam. Maximal permitted
dose to spinal cord is 45 Gy. Maximal permitted dose to
stomach and duodenum is 50 Gy for any volume of 1
mm
3.
Maintenance of Sorafenib
Sorafenib is administered only to the patients with non-
progression disease (CR, PR and SD) 4 weeks after the
completion of radiotherapy. The dose is 400 mg, p.o.,
twice a day. Sorafenib is continuously given for 12
months unless intolerable toxicities and/or tumor pro-
gression. Doses would be delayed or reduced for clini-
cally significant hematologic, or other toxicities that are
related to Sorafenib. If a patient experiences several
toxicities and there are conflicting recommendations,
the recommended dose adjustment that reduces the
dose to the lowest level would be used. All dose modifi-
cations follow the predefined dose levels (Table 5). A
grading scale is used for hand-foot skin reaction (HFS)
(Table 1), and specific dose modifications are implemen-
ted (Table 6). Non-hematologic and hematologic criteria
for dose delay and dose modification of Sorafenib are
shown in Table 2 and 3. Table 4 shows the management
procedure of hypertension resulted from Sorafenib.
Patients are followed up monthly during Sorafenib
adminstration.
Evaluation and follow-up
Treatment-related toxicity is assessed according to
CTCAE version 3.0, and is evaluated weekly during
TACE and irradiation, monthly for the period of Sorafe-
nib and every half-year thereafter. Each visit includes
physical examination, complete blood count and blood
chemistry.
Abdominal CT/MRI, chest CT, bone scan and serum
AFP are performed right after completion of TACE and
irradiation, and repeated every two months.
Sorafenib-related toxicities will be assessed during
Sorafenib administration until tumor progression. Once
intrahepatic or extrahepatic failures are suspected, the
corresponding examinations would be carried out.
Statistics
Tumor response is assessed using Response Evaluation
and Criteria in Solid Tumors (RECIST) during every
visit. Tumor progression is defined as one of the follow-
ings: (1). Hepatic tumor enlarges in size after it shrinks
or remains stable; (2). New intrahepatic lesion occurs;
(3). Extrahepatic nodes or distant metastasis develop.
The enhanced AFP level in serum after declined without
image or clinical evidences are not considered to be
tumor progression. The time from the commencement
of TACE to tumor progression is counted to get TTP.
The other endpoints are PFS and OS. All of the rates
are estimated by Kaplan-Meier method, and all observa-
tions start on the date of the first TACE. The sample
Table 5 Maintenance sorafenib dose modification table
Dose level 1 Dose level 2 Dose level 3
400 mg b.i.d 400 mg q.d 400 mg q.o.d
200 mg × 2 tablets
b.i.d (morning & evening)
200 mg × 2 tablets
q.d (morning)
200 mg × 2 tablets
q.o.d (morning)
Table 6 Skin toxicity criteria for dose delay and dose modification of sorafenib
Toxicity Grade During a Course of Therapy Dose for Next Cycle
Grade 1 Maintain dose level
# Maintain dose level
Grade 2 1st appearance Interrupt until resolved to grade 0-1 Maintain dose level
2nd appearance Interrupt until resolved to grade 0-1 400 mg every day
3rd appearance Interrupt until resolved to grade 0-1 400 mg every the other day
4th appearance Discontinue treatment permanently
Grade 3 1st appearance Interrupt until resolved to grade 0-1 400 mg every day
2nd appearance Interrupt until resolved to grade 0-1 400 mg every the other day
3rd appearance Discontinue treatment permanently
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year local progression-free rate of about 40% is based on
the result of a radiation dose escalation clinical trial
recently completed in our department with the same
TACE and radiotherapy techniques, in which the study
accumulated 40 patients (Ren ZG, Zhao JD, Gu K, et al:
Three-dimensional conformal radiation therapy and
intensity modulated radiation therapy combined with
transcatheter arterial chemoembolization for locally
advanced hepatocellular carcinoma: an irradiation dose
escalation study, submitted). This is tested against the
alternative hypothesis of a true rate of 70% or higher
with an a level of 5% and a power of 80%, which
required 24 patients according to the method proposed
by Makuch and Simon [14]. Taking the drop-out rate of
20% into consideration, a total of 30 patients will be
recruited. Accrual will be completed in 12 months. A
median follow-up period will be 30 months.
Discussion
In this study, local therapy is the combination of TACE
and radiotherapy. Necrosis after TACE is usually incom-
plete because of large tumor volume [15,16], thus 70%-
80% of patients finally succumb to intrahepatic tumor
progression [3]. A recent meta-analysis showed that
TACE in combination with radiotherapy, compared to
TACE alone, significantly improved the survival and the
tumor response, and was thus more therapeutically ben-
eficial [17]. Furthermore, implement of TACE before
radiotherapy has the additional advantages of deposited
iodine oil for target contouring and verification.
Sorafenib inhibits the activity of targets present in the
tumor cell, including members of the Raf family of ser-
ine/threonine kinases. In addition, Sorafenib inhibits
receptor tyrosine kinases, including Flt-3, kit, Ret, vascu-
lar endothelial growth factor receptor-2 (VEGFR-2), vas-
cular endothelial growth factor receptor-3 (VEGFR-3),
and platelet-derived growth factor receptor beta
(PDGFR-beta) [18,19]. Radiation exposure as a kind of
stress might induce the compensatory activations of
multiple intracellular signaling pathway mediators, such
as PI3K, MAPK, JNK and NF-kB [20]. VEGF was identi-
fied as one factor that was increased in a time- and
dose-dependent manner after sublethal irradiation
damage of HCC cells in vitro, translating to enhanced
intratumor angiogenesis in vivo and correlating well
w i t hs e r u mV E G Fl e v e l s[ 2 1 ] .T h e r e f o r e ,S o r a f e n i b -
mediated blockage of the Raf/MAPK and VEGFR path-
ways might enhance the efficacy of radiation, when Sor-
afenib is followed sequentially. In HCT116 xenograft
tumor growth delay experiments in mice, Sorafenib
altered radiation response in a schedule-dependent man-
ner. Radiation followed sequentially by Sorafenib was
found to be associated with the greatest tumor growth
delay [22].
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